SORL1 and urinary bladder carcinoma: In addition, SORLA was highly expressed in the 5637 bladder cancer cell line harbouring a HER2-activating mutation (S310F)34 when compared to the HER2-low T24 cell line and a primary patient-derived bladder cancer cell line (Supplementary Fig. 1a).